AzTrials
AzTrials

Sjögren's SyndromePhase 2SSNCT04129164

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

A Phase 2 study testing VIB4920 in people with Sjögren's Syndrome, run by Amgen at 62 sites in 12 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Sjögren's Syndrome
What is being tested?
VIB4920
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
183 participants
Where
62 sitesin 12 countries
Study dates
9 Dec 2019to 10 Mar 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed with SS by meeting the 2016 American College of Rheumatology (ACR)/EULAR Classification Criteria.
  • Residual salivary gland function as defined by whole stimulated salivary flow > 0.1 mL/min (only for Population 2).
  • Have an ESSDAI score of >= 5 at screening; (not including the peripheral nervous system, central nervous system, and pulmonary domains) (only for Population 1).
  • Have an ESSPRI score of >= 5 at screening (only for Population 2).
  • Have an ESSDAI score of < 5 at screening (only for Population 2).
  • Positive for either anti-Ro autoantibodies or rheumatoid factor, or both at screening.
  • Male and female participants who agree to follow protocol defined contraceptive methods.
  • No active or untreated latent tuberculosis (TB).

Who cannot join

  • Medical history of confirmed deep venous thrombosis or arterial thromboembolism within 2 years of signing the informed consent form (ICF).
  • Risk factors for venous thromboembolism or arterial thrombosis, prothrombotic status.
  • Concomitant polymyositis or dermatomyositis or systemic sclerosis.
  • Active malignancy or history of malignancy, except in situ carcinoma of the cervix and cutaneous basal cell carcinoma.
  • Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
  • More than one episode of herpes zoster and/or an opportunistic infection in the last 12 months.
Show all 15Show fewer
  • Active viral, bacterial, or other infections or history of more than 2 infections requiring intravenous antibiotics within 12 months prior to signing the ICF.
  • Participants with corona virus disease 2019 (COVID-19) infection or who, in the judgment of the investigator, are at unacceptable risk of COVID-19 or its complications.
  • A documented positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) test within 2 weeks prior to randomization.
  • Received live (attenuated) vaccine within the 4 weeks prior to ICF signature.
  • Treated with any biologic B-cell-depleting therapy within 12 months or other B-cell targeting therapy < 3 months before randomization.
  • Injectable corticosteroids (including intraarticular) or treatment with > 10 mg/day dose oral prednisone or equivalent within 6 weeks prior to randomization (only for Population 1).
  • Treated with systemic corticosteroids for indications other than SS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) for more than a total of 2 weeks within 24 weeks prior to screening visit (only for Population 1).
  • Received previous treatment with anti-CD40L compounds at any time before screening.
  • Pregnant or lactating or planning to get pregnant during the duration of the study.

Trial locations and contacts

62 sites in 12 countries.

62 sites in 12 countries

United States16 sites
  • Research Site

    Baltimore, Maryland, 21224

  • Research Site

    Boston, Massachusetts, 02111

  • Research Site

    Charlotte, North Carolina, 28204

  • Research site

    Dallas, Texas, 75231

  • Research site

    Duncansville, Pennsylvania, 16635

  • Research Site

    Durham, North Carolina, 27710

  • Research Site

    Fullerton, California, 92835

  • Research Site

    Houston, Texas, 77084

  • Research Site

    Houston, Texas, 77089

  • Research Site

    Kansas City, Kansas, 66160

  • Research Site

    Lawrenceville, Georgia, 30046

  • Research Site

    Memphis, Tennessee, 38119

  • Research Site

    Salisbury, North Carolina, 28144

  • Research site

    Upland, California, 91786

  • Research Site

    Wheaton, Maryland, 20902

  • Research Site

    Wilmington, North Carolina, 28401

Other trials in United States

Poland9 sites
  • Research Site

    Elblag, Elblag, 82-300

  • Research Site

    Krakow, 30-363

  • Research Site

    Lublin, 20-412

  • Research Site

    Poznan, 60-693

  • Research Site

    Siedlce, 08-110

  • Research Site

    Szczecin, 71-252

  • Research Site

    Warsaw, 02-637

  • Research Site

    Warsaw, 02-691

  • Research Site

    Wroclaw, 02-637

Other trials in Poland

India7 sites
  • Research Site

    Ahmedabad, Gujarat, 380015

  • Research Site

    Bangalore, Karnataka, 560010

  • Research Site

    Bhubaneswar, Odisha, 751005

  • Research Site

    Chennai, Tamil Nadu, 600004

  • Research Site

    Pune, Maharshtra, 411001

  • Research Site

    Pune, Maharshtra, 411013

  • Research Site

    Secunderabad, Andhra Pradesh, 5000003

Other trials in India

Italy6 sites
  • Research Site

    Brescia, Province Of Brescia, 25123

  • Research Site

    Milan, Lambardia, 20122

  • Research Site

    Perugia, Umbria, 06129

  • Research Site

    Pisa, 56126

  • Research Site

    Rome, Lazio, 00161

  • Research Site

    Udine, 33100

Other trials in Italy

France5 sites
  • Research Site

    Bordeaux

  • Research Site

    Brest

  • Research Site

    Grenoble

  • Research Site

    Paris

  • Research Site

    Strasbourg

Other trials in France

Mexico4 sites
  • Research Site

    Guadalajara, Jalisco, 44650

  • Research Site

    Guadalajara, Jalisco, 44690

  • Research Site

    Mexico City, 06700

  • Research Site

    Saltillo, Coahuila, 25000

Other trials in Mexico

South Korea4 sites
  • Research Site

    Incheon, Republic of Korea, 21565

  • Research Site

    Incheon, Republic of Korea, 22332

  • Research Site

    Seoul, Republic of Korea, 06591

  • Research Site

    Suwon, Gyeonggi-do, 16499

Other trials in South Korea

Hungary3 sites
  • Research Site

    Budapest, 1097

  • Research Site

    Debrecen, 4032

  • Research Site

    Gyula, 5700

Other trials in Hungary

Peru3 sites
  • Research Site

    Lima, San Martin de Porres, 31

  • Research Site

    Lima, 1

  • Research Site

    Lima, 33

Other trials in Peru

Taiwan2 sites
  • Research Site

    Kaohsiung City, 81362

  • Research Site

    Taichung, 40705

Other trials in Taiwan

United Kingdom2 sites
  • Research Site

    Newcastle upon Tyne, NE1 4LP

  • Research Site

    Truro, TR13LJ

Other trials in United Kingdom

Argentina1 site
  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1114AAH

Other trials in Argentina

About this study

Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Read the detailed description

The study will enrol 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity defined by European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) >= 5; Population 2 will include participants with moderate to severe subjective symptoms defined by EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score >= 5 and residual stimulated salivary flow but with mild systemic disease activity defined by ESSDAI score < 5. This study will include 3 periods: screening (4 weeks), treatment period (40 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized at 1:1 ratio to receive intravenous (IV) dose of VIB4920 or placebo (Stage I). After completion of Stage I, participants randomized to VIB4920 in Stage I will receive placebo and participants randomized to placebo in Stage I will receive VIB4920 (Stage II). Participants who had study drug discontinuation will not be eligible for treatment during Stage II. All participants will be followed for at least 12 weeks after their last dose of study drug administration.

Study acquired from Horizon in 2024.

Being tested
VIB4920, Placebo
Keywords
Sjögren's Syndrome, SS, VIB4920, MEDI4920
Medical subject headings
Sjogren's Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VIB4920Drug

    Also called Dazodalibep

    Intravenous Dose 1.

  • PlaceboDrug

    Intravenous dose matched to VIB4920.

Study groups in NCT04129164
Study groupRoleWhat they receive
VIB4920 Dose 1 in Population 1ExperimentalParticipants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Receives: Drug: VIB4920; Drug: Placebo
Placebo in Population 1Placebo comparatorParticipants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Receives: Drug: VIB4920; Drug: Placebo
VIB4920 Dose 1 in Population 2ExperimentalParticipants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
Receives: Drug: VIB4920; Drug: Placebo
Placebo in Population 2Placebo comparatorParticipants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
Receives: Drug: VIB4920; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Population 1: Change From Baseline in ESSDAI at Day 169

    The ESSDAI is a systemic disease activity index for SS, assessing 12 domains (Constitutional, Salivary Glands, Lungs, Kidneys, Musculoskeletal, Peripheral Nervous System, Central Nervous System, Vascular, Gastrointestinal, Hematological, Ocular, and Extraglandular Manifestations). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (<5), moderate (5-13), and high (≥14). A positive change form baseline represents an increase in symptoms.

    Measured: Baseline and Day 169

  2. Population 2: Change From Baseline in ESSPRI at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms.

    Measured: Baseline and Day 169

Secondary outcomes (8)
  1. Population 1: Change From Baseline in ESSPRI at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change from baseline represents an increase in symptoms.

    Measured: Baseline and Day 169

  2. Population 1: Number of Participants Who Achieved ESSDAI[3] and ESSDAI[4] Response at Day 169

    The ESSDAI is a systemic disease activity index for primary Sjögren's syndrome, assessing 12 domains (e.g., cutaneous, renal, CNS, and biological). Each domain is graded for activity (0 = no activity to 3 = high activity) and weighted (1 for Biological to 6 for Muscular) based on its clinical significance, with the final score calculated as the sum of all weighted domain scores. The theoretical range is 0 to 123, with disease activity categorized as low (<5), moderate (5-13), and high (≥14). A positive change from baseline represents an increase in symptoms.

    ESSEDAI[3] and [4] responses were defined as a decrease of at least 3 or 4 points respectively in the ESSDAI score from the baseline value, measured at Day 169.

    Measured: Day 169

  3. Change From Baseline in The Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Day 169

    The FACIT-Fatigue is a 13-item patient-reported questionnaire designed to assess the impact of fatigue on quality of life (QoL). Responses are scored from 0 (Not at all) to 4 (Very Much). The total score is the sum of all responses, ranging from 0 to 52, with higher scores indicating better QoL. A positive change from baseline represents an increase in QoL.

    Measured: Baseline and Day 169

  4. Change From Baseline in Ocular Surface Disease Index (OSDI) at Day 169

    The OSDI is a validated tool for assessing vision-related function and dry eye disease severity (normal, mild, moderate, severe). It consists of 12 questions, with responses ranging from 0 (None of the time) to 4 (All of the time). Scores range from 0 to 100, as it is calculated by transforming the raw responses from the 12 questions into a standardized 0-100 scale, with higher scores indicating greater disability. A positive change from baseline indicates a worsening vision-related function.

    Measured: Baseline and Day 169

  5. Patient Global Impression of Severity (PGIS) Score at Day 169

    The PGIS is a single-item measure that captures a patient's perception of overall symptom severity over the past week, using a 5-point categorical response scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe), with higher scores indicating greater symptom severity. Positive change from baseline values indicate worsening of symptoms severity.

    Measured: Baseline and Day 169

  6. Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169

    The ESSPRI is a self-assessment tool for evaluating symptoms of dryness, fatigue, and pain (articular and/or muscular) in SS. Participants rate each of the three domains on a 0-10 numerical scale (0 = no; 10 maximal imaginable severity). All domains are equally weighted, and the total score is the mean of the three domain scores. The maximum total score for the ESSPRI assessment is 10. A positive change form baseline represents an increase in symptoms. Participants achieving an ESSPRI response were defined as at least a 1 point or 15% reduction from baseline in ESSPRI score at Day 169 without premature discontinuation from the study and without receiving rescue medications.

    Measured: Day 169

  7. Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) referred to any untoward medical occurrence in a clinical study participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received the study treatment. Clinically significant changes in vital signs, electrocardiograms, and laboratory tests recorded after treatment administration were documented as TEAEs. Serious TEAEs (SAEs) were untoward medical occurrences after the first dose, irrespective of a causal link to the study treatment, that led to death, were life-threatening, required hospitalization or its prolongation, caused significant disability, resulted in congenital anomalies, or were considered other medically important events. AEs were graded (Grade 3: severe; Grade 4: life-threatening; Grade 5: death) using the Common Terminology Criteria for Adverse Events (CTCAE).

    Measured: Up to approximately 365 days

  8. Serum Concentration of VIB4920

    Blood samples were collected at the specified time points.

    Measured: Day 1 pre-dose, Day 1 post-dose, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141 pre-dose, Day 141 post-dose, Day 169 pre-dose, Day 169 post-dose, Day 197, Day 225, Day 253, Day 281, Day 309, Day 365

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2019
  2. Study start9 Dec 2019
  3. Primary completion1 Sep 2022
  4. Study completion10 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
183 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04129164
Sponsor's protocol ID
VIB4920.P2.S2
Other IDs
2019-002713-19, 2019
Acronym
SS
Status last verified
Apr 2025
First submitted
2 Oct 2019
Last updated
30 Apr 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W, Pham TH, Sikora K, Rees WA, Alevizos I. CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30(6):1583-1592. doi: 10.1038/s41591-024-03009-3. Epub 2024 Jun 5.

    PubMed 38839899

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing VIB4920 in people with Sjögren's Syndrome, run by Amgen at 62 sites in 12 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 62 sites in United States, Poland, India, Italy, France and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Population 1: Change From Baseline in ESSDAI at Day 169 (time frame: Baseline and Day 169). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04129164, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in